Bayer's Pipeline Wins Are Piling Up, but the Market Wants Proof in EBITDA

Two regulatory green lights and a raised earnings outlook have given Bayer shareholders plenty to cheer about. Whether the stock deserves more than that depends on a single question: can the German group turn pipeline progress into actual profit?

The answer has become more pressing because the shares have already run hard. Bayer has climbed 53% since the start of the year, according to one reading of the move — a gain that raises the bar for everything the company reports from here. A second source puts the advance at 55%. Either way, the re-rating is done; the delivery is not.

A First-in-Class Approval, and Two Very Different Reactions

At the centre of the story is Asundexian, which the US Food and Drug Administration cleared yesterday under the brand name Sunharbo. The drug lowers the risk of a repeat stroke and, according to Bayer, is the first approved factor XIa inhibitor anywhere in the world. Reuters linked the intraday share-price strength yesterday to that news.

Analysts read the same announcement in opposite directions. Jefferies' Michael Leuchten called the approval expected and said it meaningfully reduces the risk attached to Bayer's pharmaceutical pipeline — then kept his Hold rating and his €48.50 target unchanged. Deutsche Bank went the other way, lifting its price target to €65.00 from €60.00 and reiterating Buy, citing higher earnings estimates following the third quarter.

The gap between those two positions is instructive. At a closing price of €57.22, Bayer already trades above the Jefferies target, meaning anyone betting on further gains is taking a more generous view of the commercial opportunity than that house does. Deutsche Bank's more bullish number implies the opposite.

The Guidance Upgrade Is the Harder Number

Product approvals make headlines; the profit and loss account settles arguments. On that front Bayer offered something more concrete roughly a week ago with its third-quarter 2026 results: group revenue of €10.053 billion and EBITDA before special items of €1.615 billion.

Alongside those figures, the company raised its full-year forecast for adjusted EBITDA to a range of €9.8 billion to €10.3 billion. Reuters reported that management attributed the upgrade to a better-than-expected performance in the pharmaceuticals division. That detail matters more than the approval itself, because it ties the improved outlook to a specific operating engine rather than to sentiment.

China Adds a Second Regulatory Win

The pipeline story does not rest on Asundexian alone. China's National Medical Products Administration approved Sevabertinib as a first-line treatment for adults with advanced HER2-mutant non-small cell lung cancer, a decision backed by data from the SOHO-01 study.

Two approvals in quick succession strengthen the case that Bayer's development engine is producing, and they lower the binary risk that has long hung over the pharma unit. What they do not do is guarantee revenue. That translation — from regulatory milestone to income statement — is the step investors now need to see.

Roundup: One Courtroom Win in the Column

Litigation relief arrived separately. On 30 October, Bayer subsidiary Monsanto won a glyphosate case in Missouri, where the jury acquitted the company unanimously, according to dpa-AFX. A single verdict does not resolve the broader Roundup exposure, but it belongs on the positive side of the ledger and has provided tailwind for the shares.

What Would Settle the Debate

The bull case and the bear case are not really about science. They are about timing and price. If Bayer converts its approvals into revenue and keeps the pharma division supporting group earnings, the improved risk profile and the higher profit base could justify a richer valuation — the scenario Deutsche Bank is effectively underwriting.

The cautious view, embodied by Jefferies, accepts the pipeline de-risking but questions how much of it is already reflected in a stock that has gained more than half its value this year. On that reading, the distance between operating progress and market valuation becomes the vulnerability rather than the catalyst.

The next test is straightforward: further operating results and concrete evidence that the approvals are being monetised. Until then, the shares are priced for execution — and execution is the one thing Bayer has yet to show at scale.